Shares of Biogen were climbing higher on Friday after the company and Eisai announced the success of an Alzheimer’s clinical drug trial. The Phase II study had positive results with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer’s disease. “New data provide compelling evidence to further support amyloid hypothesis as a … Continue reading “Biogen Shares Explode on Positive Results from Alzheimer’s Drug Trial”
